Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

A phase 2a trial of NMD Pharma’s rare disease prospect ignaseclant has missed its primary endpoint. | A phase 2a trial of NMD ...

While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...

Exxel Pharma is eyeing a listing on the NYSE American to fund human trials for a drug class that has previously struggled to ...

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. | Quest ...

National Institutes of Health Director Jayanta Bhattacharya, M.D., Ph.D., spent much of a Senate committee hearing dancing around direct answers—except when it came to vaccines, a topic in which he ...

As the Trump administration continues to pivot away from vaccinations, it is pushing for the development of new antiviral therapies via the launch of a $100 million competition. | While the Trump ...

Charles River Laboratories is continuing its run of layoffs by announcing the closure of its cell therapy contract development and manufacturing organization (CDMO) site in Hanover, Maryland that will ...

Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema ...

Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of SanegeneBio’s ...

Daiichi Sankyo’s development of antibody-drug conjugates continues to hit turbulence. | Daiichi Sankyo’s development of ADCs ...

Sanofi’s pipeline features a number of once-hyped candidates that are struggling to deliver in the clinic, and the ...